Afficher la notice abrégée

1187MO Does the ENDOCAN-COMETE network improves the survival of adrenocortical carcinomas in France?

dc.rights.licenseopenen_US
dc.contributor.authorLIBE, R. L.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorCOUREAU, Gaelle
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorFOUCAN, Anne Sophie
dc.contributor.authorHAISSAGUERRE, Magali
dc.contributor.authorDRUI, Delphine
dc.contributor.authorGRUNENWALD, Solenge
dc.contributor.authorCASTINETTI, Frederic
dc.contributor.authorLABOUREAU, S.
dc.contributor.authorDOCAO, C.
dc.contributor.authorBORSON-CHAZOT, Francoise
dc.contributor.authorGOICHOT, B.
dc.contributor.authorLAMARTINA, L.
dc.contributor.authorCHABRE, Olivier
dc.contributor.authorMOOG, S.
dc.contributor.authorBERTHERAT, Jerome
dc.contributor.authorTABARIN, Antoine
dc.contributor.authorFARON, M.
dc.contributor.authorBAUDIN, Emmanuel
dc.date.accessioned2023-12-20T14:14:28Z
dc.date.available2023-12-20T14:14:28Z
dc.date.issued2023-10
dc.date.conference2023-10-20
dc.identifier.issn0923-7534en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/186753
dc.description.abstractEnBackground: Adrenocortical carcinoma (ACC) belongs to the family of rare cancers (annual rate of 0.72-1.3 cases/million people). The French national network « ENDOCAN-COMETE », was set up in 2009 to structure care and research on ACC patients across the country. The aim of this study was to look for the survival impact of this national network organization. Methods: ACC diagnosed between 2010 and 2017 were, first, identified from 13 cancer registries of the French network FRANCIM covering 18% of the French population. This population was described in term of characteristics, systemic managements and treatment delays. Secondly, ACC patients identified by FRANCIM were categorized as 1/ referred to one of the 11 centres of the French ENDOCAN-COMETE network at diagnosis (ACC-R) or, 2/ ACC patients lately or not referred (ACC-nR). The survival rate at 2, 3 and 5 years (2-yrs OS, 3yrs OS and 5yrs-OS) were compared, according to ENSAT stage classified as localized (stage I-II) or advanced (stage III-IV). Results: Between 2010 and 2017, 134 ACC were diagnosed in this population (mean estimated incidence of 0.14/100000 pers-yrs): 12 (9%) were stage I, 44 (33%) stage II, 17 (13%) stage III and 48 (36%) stage IV (13 patients ENSAT stage was unknown). Among them, 124 patients were analyzed (10 patients were excluded). Eighty-seven out 124 patients (70%) were referred to an ENDOCAN-COMETE network at diagnosis (ACC-R). Mean age at diagnosis was 51.5 yrs (ACC-R) vs. 58.6 (ACC-nR). Overall Survival (OS) rates of localized ACC (ENSAT stage I-II) was significantly higher in ACC-R compared to ACC-nR : 2-yrs OS was 94% vs 65%, 3-yrs OS was 90% vs 65% and 5-yrs OS was 79% vs 51%, p¼0.025 (mean OS : 6.6 vs 3.15 yrs). OS rates were similar in advanced ACC (ENSAT stage III-IV) between ACC-R vs ACC-nR. In localized ACC: 39% were ACC-R vs. 54% ACC-nR. By comparing localized ACC-R vs localized ACC-nR, we found that complete resection was found in 76% vs 68%, Weiss score median was 5 vs 5, median Ki67 was 6% vs 15%, presence of endocrine syndrome was 47% vs 35% and age was 47 vs 58 yrs, respectively. Moreover 81% of ACC-R patients received mitotane treatment vs 65% of ACC-nR. Conclusions: Our study shows a better survival of stage I-II ACC patients treated in the French ENDOCAN COMETE network.
dc.language.isoENen_US
dc.title.en1187MO Does the ENDOCAN-COMETE network improves the survival of adrenocortical carcinomas in France?
dc.typeCommunication dans un congrèsen_US
dc.identifier.doi10.1016/j.annonc.2023.09.720en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
bordeaux.pageS703-S703en_US
bordeaux.volume34en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issueSupplement 2en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.conference.titleESMO Congress 2023en_US
bordeaux.countryesen_US
bordeaux.title.proceedingAbstract Book of the ESMO Congress 2023en_US
bordeaux.teamEPICENE_BPHen_US
bordeaux.conference.cityMadriden_US
hal.identifierhal-04356247
hal.version1
hal.date.transferred2023-12-20T14:14:30Z
hal.invitedouien_US
hal.proceedingsouien_US
hal.conference.organizerIFEMA MADRIDen_US
hal.conference.end2023-10-24
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.date=2023-10&rft.volume=34&rft.issue=Supplement%202&rft.spage=S703-S703&rft.epage=S703-S703&rft.eissn=0923-7534&rft.issn=0923-7534&rft.au=LIBE,%20R.%20L.&COUREAU,%20Gaelle&FOUCAN,%20Anne%20Sophie&HAISSAGUERRE,%20Magali&DRUI,%20Delphine&rft.genre=unknown


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée